vicorepharma.comCrawled Nov 11, 2026
The page explains how ATRAGs support alveolar repair and maintenance in idiopathic pulmonary fibrosis (IPF).
The study examined C21’s effect on cold-induced vasoconstriction in patients with systemic sclerosis (SSc)-related Raynaud’s phenomenon, exploring its potential for improving blood flow in fibrotic lung diseases.
The ATTRACT study (Angiotensin II Type Two Receptor Agonist COVID-19 Trial)
The phase II study with C21 in IPF has been designed in collaboration with international clinical experts in IPF and will investigate both safety and lung function. The study aims to support the decision to initiate a confirmatory phase IIb/III study. It is a multicenter study with regulatory approvals in UK, India, Ukraine and Russia. The first patient was recruited in India in November 2020. The study is estimated to read-out in Q4, 2022.
The article by Dr. Aaron B. Holley provides a practical guide for pulmonologists managing patients with suspected idiopathic pulmonary fibrosis (IPF).
Vicore’s ATTRACT study, led by CMO Rohit Batta, investigates a potential COVID-19 treatment by exploring how the virus affects the body.
Vicore Pharma maintains close collaboration with experts to develop drugs from early stages through commercialization while controlling the full development process.
The Vicore Pharma headquarter is situated in Stockholm, Sweden.
Vicore Pharma targets treatments for diseases where the AT2-receptor plays a key role in stopping and reversing progression.
Vicore Pharma’s team, based in Sweden, focuses on improving lives of patients with rare lung diseases through a supportive, employee-centric culture.
Toby Maher is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, specializing in pulmonary fibrosis and orphan interstitial lung diseases.
Ahmed has experience in business development, portfolio strategy, and entrepreneurship in life sciences, including roles at Pieris Pharmaceuticals and legal representation for biopharmaceutical companies.
Idiopathic pulmonary fibrosis is a condition that robs patients of their ability to breathe. The associated cough can have a profound impact on the patient’s quality of life, affecting work, sleep, and personal relationships.
Vicore Pharma develops drugs to treat rare lung diseases, aiming to improve patient prognosis and quality of life.
Vicore Pharma collaborates with patient groups and supports organizations like EU-IPFF to understand experiences of idiopathic pulmonary fibrosis (IPF).
Vicore Pharma’s Phase 2b ASPIRE trial evaluates buloxibutid, a potential treatment for idiopathic pulmonary fibrosis (IPF). The trial has successfully passed a pre-planned futility analysis, indicating the study may continue to assess the drug’s efficacy. Buloxibutid targets IPF, a progressive lung disease with limited therapeutic options.
Vicore Pharma Holding’s stock price increases by 2.04% during trading on Tuesday. The company’s shares reflect investor activity amid market movements. No specific catalysts or announcements are mentioned in the report.
Vicore Pharma presents at the Stifel 2026 Virtual Immunology and Inflammation Forum. The clinical-stage biopharmaceutical company focuses on angiotensin II type 2 receptor agonists, a novel drug class. Vicore aims to unlock therapeutic potential in immunology and inflammation.
Vicore Pharma Holding AB begins trading its American Depositary Shares (ADSs) on Nasdaq US under the ticker **VCRE**, starting July 2, 2026. The company, specializing in **angiotensin II type 2 receptor agonists**, lists each ADS as representing 10 common shares. Vicore operates as a clinical-stage biopharmaceutical firm developing a novel drug class.
Vicore Pharma files for a US dual listing to expand investor access amid progress in its Phase 2b trial for **buloxibutid**, a potential treatment for idiopathic pulmonary fibrosis (IPF). The company does not plan concurrent financing or a share offering. The move follows regulatory steps to accelerate US market engagement.

A clinical-stage biopharmaceutical company, Vicore Pharma Holding develops buloxibutid, an angiotensin II type 2 receptor agonist evaluated in IPF patients.